I am no short. I actually think today's blockbuster pr is a scheme to benefit short seller. it appears they are trying to recruit suckers for short sellers and conveniently when the blockbuster shock is released later, it provides short sellers to cover and nicely profit. it smells like a scheme to me. unfortunately poor retail gets sucked to this. I got sucked to this 2 years ago. I wish SEC was a little awake
buddy joesolomon, i would rather flush dollars down the toilet than put my money here. i am just here educating people on what happened in 2012, 2011 and how investors like me lost a ton listening to the forecast made in 15 conf and investor calls, that was conveniently cut by 50% in 1 after-market pr in 2013.
Thank you Kyelion for being civil and honest.
its shameless and irresponsible. Last time when the fusilev pump was on ...105-b sales were in full swing. In fact I purchased ton of shares at $12.5 (likely sold by Raj.."tax sales" at the very same price) . Shorts knew it all along. To me it appears the knew the way sppi would release an after-market 8k despite it being gigantic news materially different from what they had been telling all along for 1.5-2 years. wouldn't such material news need an investor call to explain what went wrong and why they should still trust the management. But management chose to hide under after-market pr.
Shorts covered on that day. People like me sold to the shorts.
even until today, I believe (my opinion) the whole thing was a scheme.
WHo knew such schemes are orchestrated right under the nose of SEC?
dont get baited by "blockbuster" bs. Who knows this maybe an invitation for all the gullible investors so shorts can heavily short like they did in Fall of 2012 , when the pump on fusilev was going on.
Shorts profited heavily. Who knows who they are aligned with. They called it perfectly last time.
If i extrapolate what happened in 2012 to now, this BAIT of blockbuster bs is to facilitate shorts ? anybody?
do you even know the statistics of how many drugs FAIL in P3 ?
BTW we don't even know if this failed in P2 ?
Why even use bs words like "blockbuster announcement" soon ?
Does anyone know if the 105-b is coming soon ?!
its a shame. The drug is yet to complete its P2. Why is the streetdotcom headline calling it a blockbuster announcement soon ? Shameless of streetdotcom to publish this headline.
you said: "i don;t know how to invest so I want to blame"
So let me get this straight joe. do you invest in a company not listening to management's words ?
do you invest in companies where the management is WAY OFF (euphemism here) on their guidance ? Joe you are truly awesome.
My speculation is this guy is paid to defend the shady management that sold their stock to me at $12.5 by hyping under guise of forward looking statement.
Did mgmt really believe fusilev will grow from 2012 and did mgmt really believe in DEC 2012 that entry of generic leucovorin will not impact fusilev sales?
this guy seems to be paid to defend the management and hype the duds in the pipeline.
can anyone defend the record of this management ? virtually every forward looking statement made in 2012 is proven wrong by not a mile but 10k miles.....Fusilev, Folotyn, Zevalin
moreover we don't have access to 1000's of p2 ready or p2 completed assets of private biotech companies nor are many of these companies public.
If I was running taro, I would hire the very best biotech analysts and dedicate about 10 such analysts to scout for acquisitions.
the ONLY way to take it to the next level is getting a few specialty assets. You can't take this to the next level by just making more generics imho. By taking it to next level , i mean making this a multibagger from here...now taro sports a $7b market cap. I do think if Novexatin clinical results are successful , it can make this a mutlibagger from here. However, the company needs to have 5 novexatin-like assets (each addressing $5b market) even if they have diversify to other specialty areas like opthomology, etc. I cannot believe Gilead is $160b market cap and has made this achievement so fast .
esp after Feb 2013 the board n management have been working loyally for all shareholders. why invest in other managements?
Gilead paid $11b for pharmaasset primarily for solvadi (just started p3 trial then)....Now just that drug solvadi is clocking $12b in annual sales.
This is how right p2 or p3 specialty acquisition can add value to shareholders and take the company to the next level.
These are my forward looking statements under the SEC act of 1995 I will not revise these forward looking statements as things change. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those anticipated. Such statements are based on management's beliefs
Zevalin - can do $300m in a few years
Folotyn - we can double sales in a few years
Fusilev - we will grow
from todays SA article
"Yes, the price was steep but clearly the acquisition has been anything but a "drag on profits through 2014." Instead, Gilead executed flawlessly in rapidly bringing Sovaldi through Phase 3 studies to NDA approval in Dec 2013. In retrospect, the pricey acquisition of Pharmasset has turned out to be the most prescient deal in the pharma industry in recent memory, perhaps ever. Jeffries estimates total revenue of $200 billion to year 2030 - an average of $12.5B per year. The $11B price tag was an incredible bargain in retrospect. With the extraordinarily successful launch of Sovaldi, Gilead has become one of the most amazing stories in American industry. And the story is far from over."
the word "sustainable" needs to be defined. I have one definition. you have one. Mr Shanghvi likely has another.
as far as I am concerned, if it sustains for 2 years it is good...as then Taro with its newer pipeline will get other pricing opportunities that can more than mitigate the slack in its existing pricing opportunities when new competition enters in clobex, etc
I think taro should review this specialty opportunity
Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of back of the eye. Its principal product candidate, Fovista, is in Phase 3 clinical development for use in combination with anti-VEGF drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry and wet forms of AMD. The company was founded in 2007 and is based in New York, New York.